Business
Tetra Bio-Pharma Engages Christine Caron as Patient Partner
Tetra Bio-Pharma Engages Christine Caron as Patient Partner.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n\n\n\nTetra Bio-Pharma Engages Christine Caron as Patient Partner\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTetra Bio-Pharma Engages Christine Caron as Patient Partner\nPR Newswire\nOTTAWA, ON, July 22, 2021\n\n\n\nImportant step for Tetra to ensure meaningful collaboration and patient engagement in research. OTTAWA, ON, July 22, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Company\") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has engaged Christine Caron as Patient Partner to support significant and active collaboration in research, knowledge translation, and patient engagement within the pain and Sepsis communities.\n\n \n \n \n \n \n \n\n \nGuy Chamberland, CEO and Chief Regulatory Officer of Tetra commented \"We are very pleased to have Ms. Caron join the Tetra team as its first Patient Partner. Christine will provide valuable insights about living with post-infection and pain, due to her amputations because of Sepsis, that may validate or change the direction of concepts we explore, such as targeting outcomes that are important to patients.\" \n\"Tetra is developing a patient centric approach to better reflect patients' needs and preferences along its clinical development programs. Tetra's drug products, such as QIXLEEF™, are intended to improve pain management and quality of life, concepts that are highly subjective and directly related to the patient's reality. I'm grateful to Christine who willingly accepted to be our first Patient Partner,\" commented Aurelia De Pauw, Senior VP Clinical Programs/Medical Affairs.\nMs. Caron will be involved in reviewing and commenting on informed consent forms, questionnaires, or interview guides related to Tetra's clinical trials. She will also be assisting with knowledge translation planning and with sharing Tetra's research results with key audiences, such as the Amputee Coalition of Canada, Sepsis Canada, Global Sepsis Alliance, and Sepsis Alliance.\n\"We need to advocate and educate, because Sepsis does not di...